|
Calithera Biosciences, Inc. (CALA) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Calithera Biosciences, Inc. (CALA) Bundle
Unabhängig davon, ob Sie ein Investor oder Analyst sind, ist dieser (CALA) DCF-Taschenrechner Ihre Anlaufstelle für eine genaue Bewertung. Mit realen Daten von Calithera Biosciences, Inc. geladen, können Sie Prognosen anpassen und die Effekte in Echtzeit beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2018 |
AY2 2019 |
AY3 2020 |
AY4 2021 |
AY5 2022 |
FY1 2023 |
FY2 2024 |
FY3 2025 |
FY4 2026 |
FY5 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.3 | .0 | .0 | 9.8 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -100 | 0 | 0 | -100 | -50 | -50 | -50 | -50 | -50 |
| EBITDA | -57.3 | -88.0 | -88.3 | -115.4 | -38.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -257.4 | 100 | 100 | -1183.93 | 100 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | .5 | 1.8 | 1.9 | 1.4 | 1.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 2.27 | 100 | 100 | 14.71 | 100 | 63.4 | 63.4 | 63.4 | 63.4 | 63.4 |
| EBIT | -57.8 | -89.9 | -90.1 | -116.9 | -39.7 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -259.67 | 100 | 100 | -1198.64 | 100 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | 136.2 | 157.4 | 115.2 | 59.5 | 25.5 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.0 | .5 | 1.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 8.97 | 100 | 100 | 0 | 100 | 61.79 | 61.79 | 61.79 | 61.79 | 61.79 |
| Inventories | -2.0 | -.5 | -1.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | -8.97 | 100 | 100 | 0 | 100 | 58.21 | 58.21 | 58.21 | 58.21 | 58.21 |
| Accounts Payable | 1.2 | 2.1 | 2.0 | 3.7 | .7 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 5.6 | 100 | 100 | 37.44 | 100 | 68.61 | 68.61 | 68.61 | 68.61 | 68.61 |
| Capital Expenditure | -.2 | .0 | -.1 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -0.96162 | 100 | 100 | -1.51 | 100 | -0.49386 | -0.49386 | -0.49386 | -0.49386 | -0.49386 |
| Tax Rate, % | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 | 52.42 |
| EBITAT | -54.4 | -86.3 | -88.5 | -167.9 | -18.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -52.9 | -83.7 | -86.8 | -165.0 | -20.5 | -.7 | .0 | .0 | .0 | .0 |
| WACC, % | 3.8 | 3.87 | 3.96 | 4.03 | 1.92 | 3.52 | 3.52 | 3.52 | 3.52 | 3.52 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -24 | |||||||||
| Equity Value | 23 | |||||||||
| Diluted Shares Outstanding, MM | 5 | |||||||||
| Equity Value Per Share | 4.62 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real CALA financials.
- Real-World Data: Historical data and forward-looking estimates (as highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe how your inputs affect Calithera’s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive CALA Data: Pre-loaded with Calithera Biosciences' historical performance metrics and future projections.
- Customizable Assumptions: Tailor growth rates, profit margins, discount rates, tax assumptions, and capital investments.
- Interactive Valuation Tool: Automatic recalculation of Net Present Value (NPV) and intrinsic value based on user-defined parameters.
- What-If Analysis: Develop various forecasting scenarios to evaluate different potential valuation results.
- Intuitive User Interface: Designed for ease of use, making it accessible for both industry experts and newcomers.
How It Works
- Step 1: Download the Excel file for Calithera Biosciences, Inc. (CALA).
- Step 2: Review Calithera's pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the results and utilize them for your investment decisions.
Why Choose This Calculator for Calithera Biosciences, Inc. (CALA)?
- Accuracy: Utilizes real Calithera financial data to ensure precise calculations.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Avoid the complexities of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate Calithera Biosciences’ valuation before making stock transactions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess future projections.
- Startup Founders: Understand the valuation processes of established biotech firms like Calithera.
- Consultants: Provide detailed valuation analyses and reports for clients in the biotech sector.
- Students and Educators: Utilize current market data to study and teach valuation principles.
What the Template Contains
- Pre-Filled DCF Model: Calithera Biosciences’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Calithera Biosciences’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.